Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera
WATERTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical…
WATERTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical…
WATERTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical…
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,…
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,…
Full commercial launch of NexoBrid marks important first step to becoming the new standard of…
Full commercial launch of NexoBrid marks important first step to becoming the new standard of…
DALLAS, Sept. 20, 2023 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI”…
DALLAS, Sept. 20, 2023 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI”…
FREMONT, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading…
FREMONT, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading…
Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023…
Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023…
Strategic Realignment Designed to Right Size Organization to Address Macro Pharma Market Financing Challenges and…
Strategic Realignment Designed to Right Size Organization to Address Macro Pharma Market Financing Challenges and…
– On Track to Report Initial Data from the Global, Multiple Ascending Dose Phase 1/2…
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech…
IRVINE, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today…
DALLAS–(BUSINESS WIRE)–Flowserve Corporation (NYSE:FLS), a leading provider of flow control products and services for the…
CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset…
Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision…